Pulmonary Embolism - Pipeline Review, H2 2018

Publisher Name :
Date: 07-Aug-2018
No. of pages: 37
Inquire Before Buying

Pulmonary Embolism - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pulmonary Embolism - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Embolism - Overview
Pulmonary Embolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pulmonary Embolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pulmonary Embolism - Companies Involved in Therapeutics Development
Accu-Break Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings Co Ltd
F. Hoffmann-La Roche Ltd
Tasly Pharmaceutical Group Co Ltd
Verseon Corp
Pulmonary Embolism - Drug Profiles
DS-1040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
urokinase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
warfarin potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pulmonary Embolism - Dormant Projects
Pulmonary Embolism - Discontinued Products
Pulmonary Embolism - Product Development Milestones
Featured News & Press Releases
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon's New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pulmonary Embolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2018
Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018
Pulmonary Embolism - Pipeline by Verseon Corp, H2 2018
Pulmonary Embolism - Dormant Projects, H2 2018
Pulmonary Embolism - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Pulmonary Embolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global COPD Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the COPD partnering deals and agreements entered into by the worlds leading healthcare companies. The Global COPD Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value -......
  • Global Idiopathic Pulmonary Fibrosis Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the idiopathic pulmonary fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Idiopathic Pulmonary Fibrosis Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in par......
  • Global Pneumonia Partnering 2012-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the pneumonia partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Pneumonia Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by valu......
  • Global Idiopathic Pulmonary Fibrosis Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 27-Sep-2018        Price: US 3480 Onwards        Pages: 122
    Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen. Scope of the Report: This report studies the Idiopathic Pulmonary Fibrosis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in g......
  • Global Pneumonia Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Sep-2018        Price: US 3480 Onwards        Pages: 124
    Pneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection. Scope of the Report: This report focuses on the Pneumonia Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The emergence of advanced diagnostic techniques to be one of......
  • Global and Chinese Pneumonia Therapeutics Industry, 2018 Market Research Report
    Published: 27-Aug-2018        Price: US 3000 Onwards        Pages: 142
    The 'Global and Chinese Pneumonia Therapeutics Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Pneumonia Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pneumonia Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industr......
  • Global Idiopathic Pulmonary Fibrosis Drug Market Insights, Forecast to 2025
    Published: 21-Aug-2018        Price: US 3900 Onwards        Pages: 99
    This report studies the global market size of Idiopathic Pulmonary Fibrosis Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Idiopathic Pulmonary Fibrosis Drug in these regions. This research report categorizes the global Idiopathic Pulmonary Fibrosis Drug market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share,......
  • Global Pneumonia Therapeutics Market Insights, Forecast to 2025
    Published: 20-Aug-2018        Price: US 3900 Onwards        Pages: 91
    This report studies the global market size of Pneumonia Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pneumonia Therapeutics in these regions. This research report categorizes the global Pneumonia Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market ......
  • Global Idiopathic Pulmonary Fibrosis Market Size, Status and Forecast 2018-2025
    Published: 13-Aug-2018        Price: US 3900 Onwards        Pages: 96
    This report focuses on the global Idiopathic Pulmonary Fibrosis status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Idiopathic Pulmonary Fibrosis development in United States, Europe and China. Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen. An incre......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs